Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Plasma Fractionation Market
The global plasma fractionation market was valued at USD 37,895.55 million in 2025 and is projected to reach USD 69,156.56 million by 2035, expanding at a CAGR of 6.2% over the forecast period. Growth is driven by rising demand for immunoglobulins and increasing prevalence of immune disorders and chronic diseases. The market remains concentrated among established biopharmaceutical firms with diversified plasma-derived product portfolios.
Market size
Growth trajectory through 2035
Plasma Fractionation Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2026 Tue, 24 Mar 2026
- Market projections indicate the plasma fractionation market is expected to reach USD 51.06 billion by 2032, driven by rising demand for immunoglobulins and growing prevalence of immune disorders.
Emerging opportunities added
- Artificial Intelligence Integration AI-driven process optimization and automation in plasma fractionation can improve yield, reduce operational costs, and minimize human error, presenting a significant efficiency opportunity.
- Expansion in Emerging Markets Increasing healthcare investment and rising disease prevalence in Asia-Pacific, Latin America, and the Middle East & Africa offer growth potential for plasma-derived therapies and fractionation capacity expansion.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $37.90 Bn
- CAGR
- 6.20%
- Expansion
- 1.8×
Market shape
top segment · 59.5% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Plasma Supply Constraints
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Tue, 24 Mar 2026: Market projections indicate the plasma fractionation market is expected to reach USD 51.06 billion by 2032, driven by rising demand for immunoglobulins and growing prevalence of immune disorders
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Plasma Fractionation Market today ($37.90 Bn base), and how fast will it grow at 6.2% CAGR through 2035?
- Which of Immunoglobulins (Intravenous, Subcutaneous, Coagulation Factors and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Immunology, Hematology, Neurology applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising Demand for Immunoglobulins) and top restraints (led by Plasma Supply Constraints), with quantified CAGR impact?
- What regulatory shifts and 1 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising Demand for Immunoglobulins Immunoglobulins, particularly intravenous and subcutaneous formulations, are experiencing increased clinical use across immunology and neurology applications, driving volume growth in plasma fractionation.
- Growth in Chronic and Rare Diseases The rising prevalence of immune deficiencies, neurological disorders, and rare genetic conditions necessitates expanded access to plasma-derived therapies, supporting market expansion.
- Technological Advancements in Fractionation Innovations in processing methods, including improved viral inactivation and protein isolation techniques, enhance product efficacy and recovery rates, contributing to market growth.
Restraints
Holding it back
- Plasma Supply Constraints Ensuring a stable and sufficient plasma supply remains a persistent challenge due to donor dependency and regional collection disparities, which can limit production scalability.
- Regulatory and Compliance Costs Stringent regulatory requirements for plasma-derived products increase operational costs and extend time-to-market for new therapies, constraining smaller manufacturers.
- High Production Costs The capital-intensive nature of plasma fractionation facilities and the need for specialized infrastructure contribute to elevated production costs, impacting pricing and affordability.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Demand for Immunoglobulins | +2.8% | Global | 2025–2035 |
| Growth in Chronic and Rare Diseases | +1.7% | Global | 2025–2035 |
| Technological Advancements in Fractionation | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Plasma Supply Constraints | −1.1% | Global | 2025–2029 |
| Regulatory and Compliance Costs | −0.7% | Global | 2025–2029 |
| High Production Costs | −0.6% | Global | 2025–2029 |
Total 6 Immunoglobulins 50% Coagulation Fact 33% Albumin 17% The plasma fractionation market is segmented by product type, application, end user, and region. Product segmentation includes immunoglobulins, coagulation factors, and albumin, while applications span immunology, hematology, and neurology.
Revenue share by type · 2025 base year
% OF $37.90 BN PLASMA FRACTIONATION MARKET · 2 TYPES COVERED
Each slice = that type's share of the total $37.90 Bn Plasma Fractionation Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Immunoglobulins (Intravenous
-
Subcutaneous
-
Coagulation Factors
-
Albumin
By application
-
Immunology
-
Hematology
-
Neurology
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $37.90 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~44.1% in 2025. North America remains the largest regional market due to advanced healthcare infrastructure, high demand for plasma-derived products, and established fractionation capacity
Per-region detail
-
North America
North America remains the largest regional market due to advanced healthcare infrastructure, high demand for plasma-derived products, and established fractionation capacity
-
Europe
Europe maintains steady growth supported by strong regulatory frameworks and increasing investment in plasma collection and fractionation technologies
-
Asia-Pacific
The Asia-Pacific region is projected to witness the fastest growth, driven by rising disease prevalence, expanding healthcare access, and growing donor recruitment efforts
-
Latin America
Growth in Latin America is fueled by improving healthcare systems and increasing awareness of plasma-derived therapies for chronic and rare diseases
-
Middle East & Africa
The Middle East & Africa market is emerging, with growth potential tied to healthcare system development and partnerships with international plasma fractionation providers
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The plasma fractionation market is moderately concentrated, with a mix of large multinational biopharmaceutical companies and specialized plasma product manufacturers. Market leaders benefit from vertically integrated plasma collection and fractionation capabilities.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of plasma fractionation market?
The plasma fractionation market is worth USD 20.66 billion and is forecasted to reach above USD 32.11 billion by 2029. -
• What are some of the market's driving forces?
Alpha-1-antitrypsin and immunoglobulins are expected to be used more frequently in a variety of medical specialties worldwide, which will likely fuel market expansion. The growth of blood collection facilities around the world is another significant factor propelling the development of this market. -
• Which are the top companies to hold the market share in plasma fractionation market?
The plasma fractionation market key players include Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Biotest AG, Sanquin, Bio Products Laboratory Ltd., Intas Pharmaceuticals Ltd -
• What is the leading application of plasma fractionation market?
A vital class of medicines known as protein products fractionated from human plasma is used to prevent, manage, and treat life-threatening illnesses brought on by injury, congenital deficits, immunologic disorders, or infections. -
• Which is the largest regional market for plasma fractionation market?
North America is anticipated to have the greatest market share for plasma fractionation worldwide in 2022 because more people are using plasma fractionated goods on a regular basis and more novel items are being developed. The North America plasma fractionation market accounts of 56% of the total global market share.
The Plasma Fractionation Market is projected to reach $69.16 Bn by 2035, up from $37.90 Bn in 2025 — a 6.20% CAGR equating to roughly 1.8× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.